In 2012, Inventiva signed a multi-year drug discovery collaboration with AbbVie, which was extended in 2017. Through this collaboration, Inventiva leveraged its discovery expertise and technology platforms to develop drug candidates targeting the nuclear receptor ROR-y, a promising approach for the treatment of several autoimmune diseases, specially psoriasis in its moderate to severe form.

Inventiva’s and AbbVie’s joint efforts led to the discovery of cedirogant, a clinical stage RORγ inverse agonist, which AbbVie has stated showed promising activity as an oral psoriasis agent during its Phase Ib clinical trial.

Following these results, AbbVie announced its decision to move cedirogant into a Phase IIb dose-ranging study in the second half of 2021[1].

As part of this collaboration, Inventiva is eligible to receive development, regulatory and commercial milestone payments as well as royalty payments.

[1] See AbbVie Q1 2021 earnings call on April 30, 2021, 9 AM ET; Transcript from FactSet